Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Xbrane Biopharma.

    Client Virtual Booth

    XBRANE BIOPHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Xbrane Biopharma
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Banvaktsvägen 22 171 48 Solna Sweden
    Telephone
    Telephone
    +46 76-034 67 33
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://xbrane.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/1630164?trk=tyah&trkInfo=clickedVertical:company,clickedEntityId:1630164,idx:1-1-1,tarId:1477399504590,tas:xbrane
    Twitter
    Twitter
    https://twitter.com/XbraneBiopharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Stada and Xbrane Obtain British Approval for Ximluci® (ranibizumab) Biosimilar Referencing Lucentis®

    Details:

    Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.


    Lead Product(s): Ranibizumab

    Therapeutic Area: Ophthalmology Product Name: Ximluci

    Highest Development Status: ApprovedProduct Type: Large molecule

    Recipient: STADA Arzneimittel

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 16, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential ...

    Details:

    Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane™ and will be the Marketing Authorization Holder.


    Lead Product(s): Certolizumab Pegol

    Therapeutic Area: Immunology Product Name: Xcimzane

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Biogen

    Deal Size: $88.0 million Upfront Cash: $8.0 million

    Deal Type: Licensing Agreement February 07, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Xbrane Has Initiated Development of Two New Biosimilar Candidates, Building an Oncology Biosimilar Portfolio Targeting €23B in Annual Reference Produc...

    Details:

    Company has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio.


    Lead Product(s): Pembrolizumab

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 13, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane® (Ranibizumab) Biosimilar Product

    Details:

    The Xplore trial, which was started in 2019, is intended to study the biosimilarity of Xlucane as compared to Novartis’s Lucentis® in wet age-related macular degeneration (AMD).


    Lead Product(s): Ranibizumab

    Therapeutic Area: Ophthalmology Product Name: Xlucane

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 23, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search